NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) – supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians – today said findings from two large, international clinical trials are good news for myeloma patients, especially patients with active myeloma despite previous treatments. The newly published data demonstrate that with REVLIMID®, an oral cancer drug, all measures of myeloma showed significant and in some cases unprecedented improvement in patients where previous treatments had failed. This includes a median survival of nearly three years (35 months) with REVLIMID, the longest median survival in this difficult to treat patient group. Survival data were presented at the International Myeloma Workshop in June, and for the first time complete details from two Phase 3 clinical trials, one from the US and one from Europe, are being published simultaneously in the current issue of the New England Journal of Medicine.
